158 related articles for article (PubMed ID: 29366640)
1. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
[TBL] [Abstract][Full Text] [Related]
2. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
[TBL] [Abstract][Full Text] [Related]
3. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
5. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
6. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
7. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
[TBL] [Abstract][Full Text] [Related]
8. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H
J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449
[TBL] [Abstract][Full Text] [Related]
9. Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.
Vickers A; Vertosick EA; Sjoberg DD; Roobol MJ; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2017 Mar; 197(3 Pt 1):607-613. PubMed ID: 27693450
[TBL] [Abstract][Full Text] [Related]
10. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
12. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
[TBL] [Abstract][Full Text] [Related]
13. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume.
Vertosick EA; Zappala S; Punnen S; Hugosson J; Boorjian SA; Haese A; Carroll P; Cooperberg M; Bjartell A; Lilja H; Vickers AJ
Urology; 2021 Nov; 157():102-106. PubMed ID: 34450175
[TBL] [Abstract][Full Text] [Related]
14. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
[TBL] [Abstract][Full Text] [Related]
15. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
16. Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
Assel MJ; Ulmert HD; Karnes RJ; Boorjian SA; Hillman DW; Vickers AJ; Klee GG; Lilja H
Prostate; 2020 Jan; 80(1):51-56. PubMed ID: 31603253
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
18. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
19. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
20. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
